Continuous delta-opioid receptor activation reduces neuronal voltage-gated sodium channel (NaV1.7) levels through activation of protein kinase C in painful diabetic neuropathy
about
Roles of Voltage-Gated Tetrodotoxin-Sensitive Sodium Channels NaV1.3 and NaV1.7 in Diabetes and Painful Diabetic NeuropathyMu opioid receptors on primary afferent nav1.8 neurons contribute to opiate-induced analgesia: insight from conditional knockout miceIonic storm in hypoxic/ischemic stress: can opioid receptors subside it?Tetrodotoxin (TTX) as a therapeutic agent for pain.Are voltage-gated sodium channels on the dorsal root ganglion involved in the development of neuropathic pain?A clinical and neuropathological study of Chinese patients with diabetic peripheral neuropathy.Gene therapy for pain: results of a phase I clinical trial.Protein kinase C enhances human sodium channel hNav1.7 resurgent currents via a serine residue in the domain III-IV linker.Vector-mediated release of GABA attenuates pain-related behaviors and reduces Na(V)1.7 in DRG neurons.A novel substituted aminoquinoline selectively targets voltage-sensitive sodium channel isoforms and NMDA receptor subtypes and alleviates chronic inflammatory and neuropathic pain.Regulation of sodium channel activity by phosphorylation.Post-translational modifications of voltage-gated sodium channels in chronic pain syndromesNovel insights on diagnosis, cause and treatment of diabetic neuropathy: focus on painful diabetic neuropathyInvolvement of subtypes γ and ε of protein kinase C in colon pain induced by formalin injection.Herpes vector-mediated gene transfer in the treatment of chronic painMolecular Pharmacology of δ-Opioid Receptors.Sodium channel Nav1.7 expression is upregulated in the dorsal root ganglia in a rat model of paclitaxel-induced peripheral neuropathy.MicroRNA-30b regulates expression of the sodium channel Nav1.7 in nerve injury-induced neuropathic pain in the ratChitosan Oligosaccharide Reduces Propofol Requirements and Propofol-Related Side Effects.Diabetic painful and insensate neuropathy: pathogenesis and potential treatments.A clinical trial of gene therapy for chronic pain.Alpha-lipoic Acid and diabetic neuropathy.HSV Recombinant Vectors for Gene Therapy.New and developing drugs for the treatment of neuropathic pain in diabetes.Herpes simplex virus-based nerve targeting gene therapy in pain management.Translational pain research: Lessons from genetics and genomics.The role of sodium channels in painful diabetic and idiopathic neuropathy.Synergistic combinations of the dual enkephalinase inhibitor PL265 given orally with various analgesic compounds acting on different targets, in a murine model of cancer-induced bone pain.Neuronal growth cone retraction relies on proneurotrophin receptor signaling through Rac.From Acupuncture to Interaction between δ-Opioid Receptors and Na (+) Channels: A Potential Pathway to Inhibit Epileptic Hyperexcitability.Phenotypic changes in dorsal root ganglion and spinal cord in the collagen antibody-induced arthritis mouse model.Expression of Nav1.7 in DRG neurons extends from peripheral terminals in the skin to central preterminal branches and terminals in the dorsal horn.Antioxidant strategies in the management of diabetic neuropathy.Activation of TLR-4 to produce tumour necrosis factor-α in neuropathic pain caused by paclitaxel.Reduction of voltage gated sodium channel protein in DRG by vector mediated miRNA reduces pain in rats with painful diabetic neuropathy.Electroacupuncture Attenuates Induction of Inflammatory Pain by Regulating Opioid and Adenosine Pathways in Mice.Comparative effectiveness of antinociceptive gene therapies in animal models of diabetic neuropathic pain.Membrane protein Nav1.7 contributes to the persistent post-surgical pain regulated by p-p65 in dorsal root ganglion (DRG) of SMIR rats model.Expression and Role of Voltage-Gated Sodium Channels in Human Dorsal Root Ganglion Neurons with Special Focus on Nav1.7, Species Differences, and Regulation by Paclitaxel.DRG Voltage-gated Sodium Channel 1.7 is Up-regulated in Paclitaxel-Induced Neuropathy in Rats and in Humans with Neuropathic Pain.
P2860
Q28072725-3AFBA315-159B-4F26-B99C-56D839717879Q28533332-1D2E9F82-A3F0-4479-97D5-E5AC02E5C2D5Q33746364-EB2E2C99-68AA-47D9-B062-75F95AC31937Q34260913-E4E22EAE-CD56-4319-9AA3-BA56264EC70DQ34639336-33EB3B9F-C871-4841-9BEE-E7E5EAAA6ADAQ35117968-5352F3CB-3BDB-4FFF-BEA1-24E06DF85D27Q35154100-10173BF3-EBC2-47C1-8405-3416412E7F76Q35673535-765F1ADC-8A6E-4E0C-892B-84EDE613D54AQ35875239-AF96442F-6A4C-42C6-B619-5936A32FF989Q36011829-619D4C65-A9E4-4945-95E8-06874F73C85AQ36176745-7258DEF0-BD83-4A29-B4AA-380C62A5E799Q36249467-A8D8CD89-EDD8-4F7E-A3E9-DC235C71BBE6Q36329924-1ABBF35F-45E2-4DB5-921D-44CA7939DCEFQ36977313-8A7968BD-04B5-4984-8D08-EA52B52FED56Q37035292-9324150B-383F-4C6A-A66D-A990B42640D2Q37062556-2F90384D-FE68-4327-B09A-680305E09778Q37318012-51A4158F-AAE9-463E-8BEA-7F442C60C441Q37368204-2F576D51-B45D-47B1-997C-7DA7F5ED19EDQ37539461-4DCD925C-DCDA-4292-9C4C-79620F88882CQ37605348-ED7E2379-C070-442F-85AF-5CD441B98D37Q37612033-ABEE6580-E1E1-4727-8F64-9ED8D9C25210Q37665315-FA4C1F20-4932-4982-BA67-ED926307EC37Q37787777-A760C794-0FC2-44FB-AC80-823954616FEAQ38114817-04CEC5F5-6BBD-466A-B319-04A7F80A2332Q38182564-444198E8-14DE-4B67-8034-5DAC2E65474BQ38239812-708087C7-DCCE-42DB-AF8D-5521D8FA3B73Q38241746-41752C60-7AFD-448D-9B12-AE98ECEC6BB2Q39150711-9D563BD8-5BA6-4A8C-867D-7866EF9ACBF2Q39430718-9B845572-C1B6-407F-80DA-247FC2D3B0BEQ40191419-E1902B0F-C286-497C-9586-63A9C6051320Q41511566-82C5F938-072B-4A0C-9B5E-0238319832C3Q41901986-9C1104D9-A5C8-416E-9BCC-A1C276B93699Q42180667-C5CA5E67-638D-4D2B-B1DD-B8FAC6E5BD81Q42181695-954BE9C1-519C-4AD4-8156-6BCBACFA6B8DQ42223229-2F059470-1421-4460-BF2C-87BAD6B944E7Q44350957-42B3C26F-5AA0-4A8E-A149-F57F37D94A63Q45803169-B090C5CF-D7D7-401B-81C5-98EF085BE497Q45905935-4E045F6A-C250-4621-B6F3-FD5172DA320AQ46380475-D5E85BBE-4091-4BB1-88F7-3646DB957DDBQ47219652-42707E52-E3A7-41B2-A848-4DF96DB58BEA
P2860
Continuous delta-opioid receptor activation reduces neuronal voltage-gated sodium channel (NaV1.7) levels through activation of protein kinase C in painful diabetic neuropathy
description
2008 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունիսին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2008
@ast
im Juni 2008 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2008/06/25)
@sk
vědecký článek publikovaný v roce 2008
@cs
wetenschappelijk artikel (gepubliceerd op 2008/06/25)
@nl
наукова стаття, опублікована в червні 2008
@uk
مقالة علمية (نشرت في 25-6-2008)
@ar
name
Continuous delta-opioid recept ...... in painful diabetic neuropathy
@ast
Continuous delta-opioid recept ...... in painful diabetic neuropathy
@en
Continuous delta-opioid recept ...... in painful diabetic neuropathy
@nl
type
label
Continuous delta-opioid recept ...... in painful diabetic neuropathy
@ast
Continuous delta-opioid recept ...... in painful diabetic neuropathy
@en
Continuous delta-opioid recept ...... in painful diabetic neuropathy
@nl
prefLabel
Continuous delta-opioid recept ...... in painful diabetic neuropathy
@ast
Continuous delta-opioid recept ...... in painful diabetic neuropathy
@en
Continuous delta-opioid recept ...... in painful diabetic neuropathy
@nl
P2093
P2860
P3181
P1476
Continuous delta-opioid recept ...... in painful diabetic neuropathy
@en
P2093
David J. Fink
Marina Mata
Munmun Chattopadhyay
P2860
P304
P3181
P356
10.1523/JNEUROSCI.5530-07.2008
P407
P577
2008-06-25T00:00:00Z